IVIG IN NMO REFRACTORY/INTOLERANT TO RITUXIMAB

  • Elsone L
  • Mutch K
  • Jacob A
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Background Neuromyelitis optica (NMO) is typically a severe relapsing inflammatory disease of optic nerves and spinal cord. Prednisolone, Azathioprine, Mycophenolate and Methotrexate are commonly used first-line immunosuppressants, stepping up to Rituximab if relapses occur. Results We report 3 NMO/ NMO spectrum disorder patients who stabilised on maintenance IVIG. Case 1: A 26 year-old woman who had 11 relapses over 10 years despite multiple immunosuppressants (including Rituximab) has remained in remission for 23 months with IVIG. Case 2: A 47 year old woman with 6 relapses over 8 years despite immunosuppressants was started on Rituximab with good effect. But Rituximab had to be discontinued due to respiratory problems. After starting 6 weekly IVIG infusions she has had no further relapses after 2.8 years. Case 3: A 59 year old woman with Aquaporin-4 antibody positive NMO spectrum disorder (3 episodes of severe optic neuritis over 5 years) was intolerant to Azathioprine (leukopenia). As baseline CD 19 counts were near 0, Rituximab was not given and she was initiated on 6 weekly IVIG and remains relapse free after 11 months. Conclusions IVIG seems to be effective in preventing NMO relapses.

Cite

CITATION STYLE

APA

Elsone, L., Mutch, K., & Jacob, A. (2014). IVIG IN NMO REFRACTORY/INTOLERANT TO RITUXIMAB. Journal of Neurology, Neurosurgery & Psychiatry, 85(10), e4.65-e4. https://doi.org/10.1136/jnnp-2014-309236.157

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free